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Little inforxnation is available pertaining to infectious morbidity 
in women with genital malignancy. To define the magnitude of 
this problem, all patients admitted to the gynecologic oncology 
services at the University of Michigan Medical Center between 
January 1, 1986, and December 31, 1986, were followed pros- 
pectively for the development of infectious morbidity. One 
hundred nine bacteriologically confirmed infections occurred in 
297 patients during 510 admissions. An additional 31 postoper- 
ative patients received empiric therapy for presumed infection. 
Urinary tract (54) and wound (22) infections were the most com- 
monly confirmed infections. The pathogens isolated from oncol- 
ogy patients were significantly different in frequency of isolation 
and antibiotic sensitivity when compared with pathogens isolated 
from women developing infections on the benign gynecology ser- 
vice. Women with genital malignancies are at high risk for the 
development of a variety of infections by resistant pathogens, 
emphasizing the importance of obtaining cultures prior to initi- 
ation of therapy and carefully selecting the antibiotics to be pre- 
scribed. 01990AC&dClUiCPPZ?S,hC. 
Genital malignancy constitutes approximately one- 
fourth of invasive cancers diagnosed in women. Therapy 
oftentimes consists of a combination of surgery, radiation 
therapy, and chemotherapy. These patients may be at 
high risk for infectious morbidity for a number of rea- 
sons. Frequently patients with endometrial cancer are 
obese and, at a referral center such as the University of 
Michigan Medical Center, weigh more than 300 pounds. 
The increased use of lymph node dissection in surgery 
for pelvic malignancies extends the time of operation 
and allows for accumulation of blood and body fluid in 
devascularized tissue. Patients with ovarian carcinoma 
and those undergoing pelvic exenteration present the 
possibility for a unique bacteriologic spectrum to be en- 
countered: not only will the vagina be entered, but when 
bowel surgery is required the patient is at risk for bac- 
terial contamination from multiple sites. These patients 
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are usually in an older age group and may have a de- 
pressed immune status. Lastly, the nutritional status of 
these patients is often borderline, especially in the obese 
patient or in women with advanced stages of cancer. 
During the past two decades, great advances have been 
made in understanding the microbiology, pathophysiol- 
ogy, and treatment of the common obstetric and gyne- 
cologic infections, including postpartum endoparametri- 
tis, pelvic cellulitis, and other community acquired 
infections such as pelvic inflammatory disease. It must 
be assumed that the majority of clinicians have relied on 
these data when treating the gynecologic oncology pa- 
tient. With the use of radiation therapy, chemotherapy, 
and extended surgery in these patients, it seems unwise 
to make this assumption. Since the report by Ledger et 
al. [l] of infectious morbiidty and sepsis on a gynecology 
service in the early 197Os, little additional information 
has been made available with respect to gynecologic on- 
cology patients. Thus, a yearlong survey of bacterial 
infections on a gynecologic oncology service was un- 
dertaken; additionally, bacterial isolates from the on- 
cology patients are compared to pathogens isolated from 
women developing infections hospitalized on the benign 
gynecology service during the same period. 
MATERIALS AND METHODS 
From January 1, 1986, thru December 31, 1986, all 
patients admitted to the gynecologic oncology service at 
the University of Michigan Medical Center were pros- 
pectively monitored for the development of infections 
acquired during hospitalization. Patients were listed in a 
registry on the day of admission and charts were re- 
viewed on a daily basis. Following discharge, the charts 
were again reviewed and microbiologic data gathered. 
The diagnosis of infection was based on clinical and 
laboratory parameters. Cultures including blood, urine, 
wound, abscess, operative site, intravenous lines, and 
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miscellaneous body fluids were obtained in nonsurgical 
patients exhibiting temperature greater than 38°C and in 
postoperative patients with temperature greater than 38” 
C on two occasions 6 hr apart excluding the first 24 hr. 






All patients with a bacterial growth 
of greater than 10’ colonies of a single 
pathogen per milliliter of urine in 
midstream clean-voided specimen. 
Urine specimens obtained by urinary 
catheter yielding one or more uro- 
pathogens were felt to represent 
bacteriuria. 
All inflamed surgical wounds with 
purulent drainage and confirmed by 
microbiologic studies. 
Patients with physical examination 
and x-ray findings consistent with 
pneumonia, most were confirmed by 
gram stain and culture. 
Postoperative patients exhibiting 
pyrexia, lower abdominal pain, tend- 
erness and induration on pelvic exam 
with supporting laboratory studies 
(including leukocytosis). A Specimen 
for culture was not routinely obtained 
from the vaginal cuff on the oncology 
or benign gynecology service. 
Microbiology. Microorganisms were isolated and iden- 
tified by standard microbiologic techniques. Sensitivities 
were determined by a microdilution method. 
Antimicrobial prophylaxis. Parenteral prophylactic an- 
tibiotics included cefazolin 1 g every 8 hr or cefoxitin 
l-2 g every 6 hr for 24-48 hr at the discretion of the 
attending physician. Patients with significant risk for 
bowel entry routinely had bowel cleansing consisting of 
erythromycin 500 mg and neomycin 1 g orally every 6 
hr for at least 24 hr prior to surgery and a neomycin 
enema the morning of surgery. 
Statistical Analysis. Data were analyzed using the x2 
or Fishers’s exact test where appropriate. 
RESULTS 
During the study period there were a total of 510 ad- 
missions to the gynecologic oncology service involving 
297 patients. The most common reason for admission 
was surgery (n = 218), followed by chemotherapy (n = 
192) and radiation therapy (n = 38). Patient admissions 
by origin of malignancy are noted in Table 1. 
There were 109 bacteriologically confirmed infections 
in the study group (Table 2). An additional 31 patients 
TABLE 1 





Fallopian tube 8 
Vagina 4 
Uncertain 12 
received empiric therapy for pelvic cellulitis or urinary 
tract infection not confirmed by microbiologic studies. 
Urinary tract infection (n = 54) was the most common 
microbiologically confirmed infection followed by wound 
infection (n = 22) and pneumonia (n = 15). Six of eight 
patients with multiple infections (n = 20) had undergone 
radical pelvic procedures, including total pelvic exen- 
teration (n = 3), radical vulvectomy (n = 2), and radical 
hysterectomy (n = 1). 
There were 136 organisms isolated from the patients 
(Table 3). Escherichia coli was the most common of 26 
different isolates. Other frequently isolated organisms 
include Pseudomonas aeruginosa and group D 
enterococcus. 
During the study period 525 patients were admitted to 
the benign gynecology service. The bacteria isolated 
from these women developing infections were signifi- 
cantly different in the frequency of recovery (Table 4) 
and antibiotic sensitivity trends (Table 5) from those in 
oncology patients. E. coli was the most common organ- 
ism isolated from both patient groups and was more 
frequently recovered from benign gynecology patients (P 
< 0.0005). E. coli isolates from both services were similar 
with respect to sensitivity to commonly prescribed an- 
timicrobials including ampicillin, cefoxitin, and genta- 
micin. P. aeruginosa represented 15% of total isolates 
from the oncology infections although there were only 
3 (3.2%) from infections in benign gynecology patients 
(P < .Ol). Isolates from both services were highly re- 
sistant to first- and second-generation cephalosporins, 
but were sensitive to most third-genertion cephalospo- 
rins. All isolates from benign gynecology patients were 
sensitive to gentamicin; however, 25% of P. aeruginosa 
TABLE 2 
Bacteriologically Confirmed Infections in Gynecologic Oncology 
Patients (N = 109) 
Urinary tract infection 54 
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TABLE 3 
Pathogens Isolated from Gynecologic Oncology Patients (Total 
and Source) 
Organism Total Urine Wound Other 
Escherichia coli 26 18 5 3 
Pseudomonas aeruginosa 18 9 6 3 
Group D enterococcus 16 8 6 2 
Staphylococcus epidermidis 15 10 5 
Klebsiella pneumoniae 8 3 1 4 
Enterobacter cloacae 7 2 3 2 
Candida albicans 7 6 1 
Proteus vulgaris 5 5 
Proteus mirabilis 7 4 3 
Staphylococcus aureus 5 2 2 1 
Clostridium perfringens 3 3 
Klebsiella oxytoca 2 2 
Bacteroides fragilis 2 2 
Citrobacter diversus 2 2 
Enterobacter aerogenes 1 1 
Morganella morgani 1 1 
Providencia stuartii 1 1 
Pseudomonas putida 1 1 
Lactobacillus sp. 1 1 
Diptheroids 1 1 
Capnocytophagia sp. 1 1 
Penicillium sp. 1 1 
Haemophilus influenzae 1 1 
Clostridium ramosum 1 1 
Peptostreptococcus sp. 1 1 
Acinetobacter sp. 1 1 
Group B streptococccus 1 1 
isolates from oncology patients were resistant to gen- 
tamicin. Additionally, 36% of gentamicin-sensitive P. 
aeruginosa isolates were determined to be of interme- 
diate sensitivity to gentamicin as determined by micro- 
diluation method. Of other facultative gram-negative 
rods, Proteus sp. and Klebsiella sp. were sensitive to 
first- and second-generation cephalosporins. Enterobac- 
ter cloacae were resistant to first- and second-generation 
cephalosporins and one E. cloacae isolate was resistant 
to several third-generation cephalosporins tested. Both 
TABLE 4 
Pathogens Isolated from Benign Gynecology Patients 
Organism Total Urine Wound Other 
Escherichia coli 42 29 4 
Proteus mirabilis 6 5 
Citrobacter freundi 4 3 
Klebsiella pneumoniae 9 3 1 
Pseudomonas aeruginosa 3 2 
Enterobacter cloacae 3 2 
Enterococcus 8 2 
Coagulase-positive staphylococcus 4 2 1 1 
Coagulase-negative staphylococcus 11 6 2 2 
Bacteroides fragilis 2 
Other 8 3 1 
TABLE 5 
Comparison of Sensitivity Patterns of Pathogens Isolated for 
Patients on the Gynecology Services 
Percentage of 










Antibiotic Benign Oncology 
Penicillin 0 0 
Vancomycin 100 100 
Penicillin 20 0 
Vancomycin 100 100 
Ampicillin 67 75 
Cefoxitin 90 100 
Gentamicin 100 100 
Cefoxitin 0 0 
Gentamicin 100 75 
coagulase-positive and coagulase-negative staphylococci 
were frequently isolated from both services, with isolates 
from the benign gynecology service exhibiting modest 
sensitivity to commonly prescribed penicilins and ceph- 
alosporins. Isolates from oncology patients were uni- 
formly resistant to all antimicrobials except vancomycin. 
DISCUSSION 
Since the report by Ledger et al. [l] in 1972, little has 
been reported on infections in gynecologic oncology pa- 
tients. In the ensuing 17 years, however, significant ad- 
vances in the care of women with genital malignancies 
have occurred, including surgical technique and selection 
of surgical candidates, introduction of new chemother- 
apeutic agents, introduction of new broad-spectrum an- 
tibiotics, and the routine use of perioperative prophy- 
lactic antibiotics. Ledger et al. studied the infectious 
morbidity on the Gynecology Service at the University 
of Michigan Medical Center that included 119 patients 
with genital malignancies; nearly half (n = 50) were 
admitted for medical indications or radiation therapy. In 
their report, 52% of women with genital malignancies 
admitted for nonsurgical reasons experienced febrile 
morbidity and 36% received antibiotics. In the current 
report, infections were diagnosed in 5.7% of admissions 
for chemotherapy and 13% of admissions for radiation 
therapy. Reasons for this reduction in infectious mor- 
bidity are unclear; however, they may include improve- 
ments in infection control and more experience with 
chemotherapeutic agents. Since we studied all patients 
prospectively, underreporting of infections in the current 
series is not possible. 
Ledget et al. noted the prevalence of postoperative 
infections to be highest among oncology patients. Of 69 
surgical patients in his series, 56 (81%) experienced fe- 
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brile morbidity while 54 (78%) received antibiotics. He 
noted patients undergoing radical surgical procedures to 
be at highest risk for infectious morbidity (86%). Of the 
218 admissions for surgery in the current study, 75 mi- 
crobiologically confirmed infections occurred in 62 (28%) 
patients, while 31 (14%) patients received empiric ther- 
apy for suspected pelvic cellulitis or urinary tract infec- 
tion. After allowing for multiple infections, the infectious 
morbidity in surgical patients is approximately 43%, half 
that reported by Ledger et al. In a retrospective study 
of hospital admissions of gynecologic oncology patients, 
Brooker et al. [2] reported that 11% of patients developed 
serious infections, which was not defined. Due to the 
retrospective nature of this study and the exclusion of 
uncomplicated urinary tract infections and other “less 
serious” infections from the data base, the overall in- 
fectious morbidity would be underestimated. The current 
prospective study included all microbiologically con- 
firmed infections and presumed postoperative infections 
such as pevic cellulitis and may be more representative 
of infectious morbidity in women with gential 
malignancy. 
Procedures with the potential for lower morbidity, i.e., 
staging laparotomy for cervical cancer and second-look 
laparotomy for ovarian carcinoma, may contribute to the 
lower infection rate in the current study. Other retro- 
spective studies report a low incidence of infectious mor- 
bidity in patients undergoing radical hysterectomy [31 
(14% major and minor infections), although infections 
were common in patients undergoing pelvic exenteration 
(pelvic cellulitis 70%, abdominal wound infection 28%, 
pyelonephritis 15%, and sepsis 15%) [4]. 
A likely factor in the reduction of infectious morbidity 
during this period is the use of perioperative antimicro- 
bial prophylaxis, administered prior to 181 of 218 (83%) 
procedures. Investigators have demonstrated the benefit 
of a bowel prep as used in this series in reducing mor- 
bidity in bowel surgery [S]. Parenteral prophylactic an- 
tibiotics have not been studied extensively in radical 
pelvic surgery. There are no prospective controlled trials 
evaluating the efficacy of parenteral prophylactic anti- 
biotics for radical vulvectomy or pelvic exenteration, 
although these procedures appear to be associated with 
a very high risk for infectious morbidity to justify par- 
enteral antimicrobials. In placebo controlled studies, Ro- 
senshein et al. [6] found single-dose vibramycin to sig- 
nificantly reduce the incidence of febrile morbidity and 
infectious morbidity in patients undergoing radical hys- 
terectomy; likewise, Micha et al. [7] found three-dose 
mezlocillin to significantly reduce the fever index and 
the incidence of operative site infections. Certainly ad- 
ditional studies are necessary to further define the role 
and duration of administration of prophylactic antibiotics 
in this population at high risk for infection. 
Traditionally, obstetric and gynecologic infections are 
considered mixed polymicrobial infections. Frequently 
isolated organisms include anaerobic gram-positive 
cocci, anaerobic gram-negative rods, facultative gram- 
negative rods including E. coli, and group B /3-hemolytic 
streptococcus. In a study in obstetric and benign gy- 
necologic patients, Herd et al. reported that 204 of 208 
gram-negative rods were sensitive to gentamicin at ~4 
pg/ml[8]. As in our report, E. coli was the most frequent 
gram-negative isolate and except for ampicillin, antibiotic 
resistance was uncommon. Of note, approximately one- 
fifth of the gram-negative rods recovered from cancer 
patients and tested for susceptibility to gentamicin had 
minimum inhibitory concentrations exceeding 4 pg/ml 
(P < 0.025). Resistant P. aeruginosu is an uncommon 
pathogen in healthy patients and seems unique to this 
population. Enterococcus was isolated frequently from 
women on both gynecology services (P > 0.05) and likely 
reflects the widespread use of cephalosporin prophylaxis 
as was recently described by Faro et al. [93 Factors 
contributing to the high prevalence of these organisms 
or antibiotic resistance in gynecologic oncology patients 
include (1) the need for multiple and prolonged hospi- 
talizations allowing for colonization, (2) prior antibiotic 
therapy or prophylaxis allowing for induction of antim- 
icrobial resistance or predisposing to overgrowth or su- 
perinfection with hospital-acquired pathogens, and (3) 
underlying malignancy or chemotherapy altering host re- 
sistance. It is most important to recognize that infections 
in gynecologic oncology patients are frequently caused 
by resistant pathogens and proper selection of antimi- 
crobial agents should reflect this awareness. After em- 
piric therapy is initiated, it is imperative that results of 
cultures be obtained, sensitivities determined, and the 
most appropriate antibiotic prescribed. 
In summary, this study defines the infectious morbidity 
on a gynecologic oncology service. It appears that over 
a 17-year period, the prevalence of infectious morbidity 
has declined at the authors’ institution. Many of the 
infections and the microbiolgoy are unique to this patient 
population. Additional studies are needed to further de- 
fine infectious morbidity as well as antimicrobial therapy 
and prophylaxis in women with genital malignancy. 
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